mirtazapine has been researched along with Common Variable Immunodeficiency in 2 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Common Variable Immunodeficiency: Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Demonstration of survival and outcome of progressive multifocal leukoencephalopathy (PML) in a 56-year-old patient with common variable immunodeficiency, consisting of severe hypogammaglobulinemia and CD4+ T lymphocytopenia, during continuous treatment with mirtazapine (30 mg/day) and mefloquine (250 mg/week) over 23 months." | 7.81 | Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. ( Bassetti, CL; Du Pasquier, R; Furrer, H; Hirsch, HH; Kardas, P; Krestel, H; Kurmann, R; Lämmle, B; Sturzenegger, M; Weisstanner, C; Wiest, R, 2015) |
| "Demonstration of survival and outcome of progressive multifocal leukoencephalopathy (PML) in a 56-year-old patient with common variable immunodeficiency, consisting of severe hypogammaglobulinemia and CD4+ T lymphocytopenia, during continuous treatment with mirtazapine (30 mg/day) and mefloquine (250 mg/week) over 23 months." | 3.81 | Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. ( Bassetti, CL; Du Pasquier, R; Furrer, H; Hirsch, HH; Kardas, P; Krestel, H; Kurmann, R; Lämmle, B; Sturzenegger, M; Weisstanner, C; Wiest, R, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McLean-Tooke, A | 1 |
| Phatouros, CC | 1 |
| Chidlow, G | 1 |
| Smith, DW | 1 |
| Silbert, P | 1 |
| Kurmann, R | 1 |
| Weisstanner, C | 1 |
| Kardas, P | 1 |
| Hirsch, HH | 1 |
| Wiest, R | 1 |
| Lämmle, B | 1 |
| Furrer, H | 1 |
| Du Pasquier, R | 1 |
| Bassetti, CL | 1 |
| Sturzenegger, M | 1 |
| Krestel, H | 1 |
2 other studies available for mirtazapine and Common Variable Immunodeficiency
| Article | Year |
|---|---|
Granule Cell Neuronopathy in a Patient with Common Variable Immunodeficiency.
Topics: Common Variable Immunodeficiency; Female; Humans; JC Virus; Mefloquine; Middle Aged; Mirtazapine; Ne | 2019 |
Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine.
Topics: Antiviral Agents; Common Variable Immunodeficiency; DNA, Viral; Humans; JC Virus; Leukoencephalopath | 2015 |